PUBLICATIONS
研究論文
-
31. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, (Li CW), Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC* Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Molecular cell 71(4), 606-620.e7 (2018) [JCR] [WOS] -
32. Hsu JM#, (Li CW#), Lai YJ, Hung MC*, # Contributed equally Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer research 78(22), 6349-6353 (2018) [JCR] [WOS] -
33. Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, (Li CW), Lim SO, Chang SS, Chen YC, Ren GX, Hung MC* STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature communications 9(1), 1908 (2018) [JCR] [WOS] -
34. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, (Li CW), Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC* PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical cancer research : an official journal of the American Association for Cancer Research 23(14), 3711-3720 (2017) [JCR] [WOS] -
35. (Li CW#), Lim SO#, Hsu JL, Hung MC*, # contributed equally Rational combination of immunotherapy for triple negative breast cancer treatment. Chinese clinical oncology 6(5), 54 (2017) [JCR] [WOS] -
36. (Li CW), Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC* AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer research 76(6), 1451-62 (2016) [JCR] [WOS] -
37. Lim SO#, (Li CW#), Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC*, # contributed equally Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer cell 30(6), 925-939 (2016) [JCR] [WOS] -
38. Lim SO, (Li CW), Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC* EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer research 76(5), 1284-96 (2016) [JCR] [WOS] -
39. (Li CW#), Lim SO#, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC*, # contributed equally Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature communications 7, 12632 (2016) [JCR] [WOS] -
40. Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, (Li CW), Wei Y, Nie L, Yamaguchi H, Hung MC* GSK3beta inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7(35), 57131-57144 (2016) [JCR] [WOS]
| Record 31 to 40, total of 58 records |